Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Kyle R Crassini, MBBS, BSc, Yandong Shen, BMedSc (Hon), William S. Stevenson, MBBS, PhD, Stephen P. Mulligan, PhD, FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc, Richard Christopherson, PhD Emeritus Professor

Blood (2018) 132 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2018-99-118264

Published: 2018

Journal Articles

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS, BSc, Michael E O'Dwyer, MD, Michael Francis O'Neill, PhD BA, Richard Christopherson, PhD Emeritus Professor, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2018-99-115574

Published: 2018

Journal Articles

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Jane A. Freeman, BA, FRACP, FRCPA, MBBS, MPhil, MSc, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Richard Eek, MBCHB, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Nicholas E. Murphy, FRCPA, MBBS, FRACP, Duncan P. Carradice, MBBS, FRCPA, FRACP, Ann C. Solterbeck, BSc(hons) MSc PhDAStat, Oliver Giles Best, PhD BSc, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 3144.

https://doi.org/10.1182/blood-2018-99-116287

Published: 2018

Journal Articles

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Narjis Rizwan, BSMedTech, MPhil, PhD, Yandong Shen, BMedSc (Hon), Edwin Iwanowicz, PhD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Kyle R Crassini, MBBS, BSc, Richard Christopherson, PhD Emeritus Professor, Oliver Giles Best, PhD BSc

Blood (2018) 132 (Supplement 1): 3145.

https://doi.org/10.1182/blood-2018-99-115555

Published: 2018

Journal Articles

Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Isabelle G. Solman, MS, Marlene Taylor, MS, Hana You, MS, Susan M. O'Brien, MD, Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, John C. Byrd, MD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Ann Mongan, PhD

Blood (2018) 132 (Supplement 1): 3114.

https://doi.org/10.1182/blood-2018-99-110848

Published: 2018

NARROW

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Email alerts

ASH Publications

American Society of Hematology

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53 -Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment

Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy

ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment

Ibrutinib Treatment Improves T-Cell Proliferative Ability and Effector Function in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only